Steroid Dosing in Pemphigus Vulgaris
Start with oral prednisolone 1 mg/kg/day for most cases of pemphigus vulgaris, or 0.5-1 mg/kg/day for milder disease, and always combine with an adjuvant immunosuppressant from the outset. 1
Initial Dosing Strategy
The British Association of Dermatologists 2017 guidelines provide the most authoritative framework for steroid dosing in pemphigus vulgaris:
Starting Dose
- Standard cases: Prednisolone 1 mg/kg/day (or equivalent)
- Mild cases: Prednisolone 0.5-1 mg/kg/day
- Severe cases: Consider pulsed IV methylprednisolone (10-20 mg/kg or 250-1000 mg for up to 5 consecutive days) followed by 1 mg/kg/day oral prednisolone 1
This moderate approach is evidence-based: an RCT comparing low-dose (30-60 mg/day) versus high-dose (120-180 mg/day) prednisolone showed no significant difference in disease control or relapse rates at 5 years, but importantly, up to 77% of deaths in pemphigus have been corticosteroid-related 1. The era of very high doses (120-400 mg/day) is over due to unacceptable toxicity.
Dose Escalation Protocol
If no response within 5-7 days, increase the dose by 50-100% increments until disease control is achieved (defined as no new lesions and healing of pre-existing ones) 1.
If you require more than 1 mg/kg/day oral prednisolone, switch to pulsed IV corticosteroids rather than continuing to escalate oral doses 1.
Treatment failure is formally defined as failure to achieve disease control despite 3 weeks of prednisolone 1.5 mg/kg/day (note: this is 15 mg/kg in the text, which appears to be a typo) or equivalent 1.
Tapering Strategy
Once remission is induced and maintained (absence of new blisters and healing of majority of lesions):
- Begin tapering the dose
- Target: reduce to ≤10 mg daily 1
- Clinical improvement typically occurs within days, cessation of blistering takes 2-3 weeks, and full healing may take 3-8 weeks 1
Critical caveat: Do not withdraw treatment prematurely. Relapse rates are high—47% of successfully treated patients relapsed when treatment was stopped after only 1 year 1. However, complete remission off-therapy is achievable in 38%, 50%, and 75% of patients at 3,5, and 10 years, respectively 1.
Mandatory Adjuvant Therapy
Always combine corticosteroids with an adjuvant immunosuppressant from the start 1. The 2017 landmark RCT demonstrated that rituximab combined with short-term prednisolone achieved 89% complete remission off all treatment at 2 years versus only 28% with prednisolone alone 1. This represents a paradigm shift in pemphigus management.
First-line adjuvant options:
- Rituximab: 2 × 1 g infusions, 2 weeks apart (rheumatoid arthritis protocol) 1
- Azathioprine: 2-3 mg/kg/day (if TPMT normal) 1
- Mycophenolate mofetil: 2-3 g/day 1
These agents are more important for remission maintenance than induction due to delayed onset of action 1.
Special Considerations
Pulsed IV Corticosteroids
While theoretically attractive, monthly oral dexamethasone pulses showed no additional benefit and more adverse effects in a double-blind RCT 1. However, IV methylprednisolone pulses may be useful for severe disease or when oral doses exceed 1 mg/kg/day 1.
Osteoporosis Risk
Assess osteoporosis risk immediately upon starting corticosteroids 1.
Disease Severity Tailoring
Recent retrospective data suggests that higher initial doses (1.21-2.0 mg/kg/day methylprednisolone) in moderate disease achieved faster disease control (median 8.5 days) and shorter hospital stays without increasing cumulative corticosteroid doses 2. However, this conflicts with guideline recommendations and requires prospective validation.
The key to successful pemphigus management is balancing rapid disease control against minimizing cumulative steroid exposure through early use of effective adjuvant therapy, particularly rituximab.